Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 4/2019

THERAPEUTIC EFFECTS OF ALOPERINE ON THE PULMONARY ARTERIAL HYPERTENSION

SHUANG LI 1, FUBO ZHOU 2, JIANJIANG DONG 3, QI DONG 1, HAIRONG LUAN 1, LI LI 1, YANKUN HAO 1*

1.Department of Medical Function, Mudanjiang Medical University, Mudanjiang 157011, People’s Republic of China
2.Department of Pharmacology, Mudanjiang Medical University, Mudanjiang 157011, People’s Republic of China
3.Department of Histology and Embryology, Mudanjiang Medical University, Mudanjiang 157011, People’s Republic of China

Download Full Article PDF

In order to study the therapeutic effect of aloperine (ALO) on the pulmonary arterial hypertension (PAH), 90 male Sprague Dawley (SD) rats were divided into six groups: sham group, PAH group, PAH + 25 mg/kg bw ALO group, PAH + 50 mg/kg bw ALO group, PAH + 100 mg/kg bw ALOgroup, and PAH + 25 mg/kg bw sildenafil group. The hemodynamic parameters, pulmonary fibrosis, vascular endothelial cell structure, intercellular monocyte chemotactic protein-1 (MCP-1) (adhesion factor-1) and ET-1 (endothelin-1) expression levels, and the expression levels of nuclear factor kappa light chain enhancer of activated B cells (NF-κB), tumour necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) pathways were assayed by Western blotting in order to evaluate the influence of ALO on PAH. It was revealed that after the successful establishment of monocrotaline-induced PAH models in rats, rats showed decreased wall thickness of pulmonary arterioles, vascular stenosis, irregular swelling of vascular endothelial cells, proliferation of pulmonary fibrous tissues, disordered arrangement, increased number of MCP-1 and ET-1 cells, and increased expression levels of NF-κB, TNF-α, and IL-1β pathways. Sildenafil is well known to have protective effects on PAH. According to the achieved results, it can be concluded that ALO also has protective effects on PAH. ALO could improve the development of PAH through the NF-κB p65 signalling pathway.